<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>BAP1-inactivated melanocytoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">BAP1-inactivated melanocytoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">BAP1-inactivated melanocytoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jinah Kim, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond L Barnhill, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1322395119"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>BAP1-inactivated melanocytomas (BIMs) are rare melanocytic tumors characterized by the loss of nuclear expression of the BRCA1-associated protein-1 (BAP1), a nuclear protein encoded by the <em>BAP1</em> tumor suppressor gene. BIMs, which clinically resemble intradermal nevi or dermatofibromas and were initially considered atypical Spitz tumors, can occur sporadically or in the setting of BAP1 tumor predisposition syndrome. First described in 2011, BAP1 tumor predisposition syndrome (MIM #614327) is a rare autosomal dominant tumor predisposition syndrome caused by germline variants in the <em>BAP1</em> tumor suppressor gene [<a href="#rid1">1,2</a>].</p><p>Carriers of <em>BAP1</em> variants have an increased risk of developing a variety of tumors, including uveal melanoma, malignant mesotheliomas, cutaneous melanoma, renal cell carcinoma, basal cell carcinoma, hepatocellular carcinoma, and cholangiocarcinoma [<a href="#rid1">1,3-10</a>]. Most affected individuals also develop multiple cutaneous BIMs, which were previously considered atypical Spitz tumors [<a href="#rid11">11,12</a>].</p><p>This topic will discuss the pathogenesis, diagnosis, and management of BIMs. Spitz tumors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p class="headingAnchor" id="H4289902097"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span><span class="headingEndMark"> — </span>BIMs were previously referred to as Wiesner nevi, BAPomas, BAP1 mutant Spitz nevi, melanocytic BAP1-mutated atypical intradermal tumors (MBAITs), or BAP1-inactivated melanocytic tumors (BIMTs) [<a href="#rid11">11</a>]. In this topic, we will use the term "BAP1-inactivated melanocytoma" (BIM).</p><p>The fifth edition of the World Health Organization (WHO) Classification of Skin Tumours Online includes two entities classified as intermediate/low-grade dysplasias and intermediate/high-grade dysplasias, respectively called "BAP1-inactivated melanocytoma" and "BAP1-inactivated melanocytoma/melanocytic tumor of uncertain malignant potential"  (<a class="graphic graphic_table graphicRef129801" href="/z/d/graphic/129801.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. In the revised Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx version 2.0) schema, BIM is categorized as class II [<a href="#rid14">14</a>].</p><p>Although severely atypical variants of BIMs with uncertain malignant potential are recognized, such tumors and malignant variants are extremely rare. BIMs represent a spectrum of neoplasia in which true malignancy is difficult to conclusively substantiate except by proof of distant metastasis or death. This is because convincing clinical, histopathologic, and genetic data are not available for a sufficient cohort of patients with sufficiently long follow-up to draw definitive conclusions.</p><p class="headingAnchor" id="H1221408766"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence and prevalence of BIMs are not known. BIMs can appear at any age, most often in the second or third decade of life, without sex predilection [<a href="#rid11">11</a>]. They can occur sporadically or be a manifestation of BAP1 tumor predisposition syndrome, associated with autosomal dominant <em>BAP1</em> germline variants.</p><p>The true prevalence of germline <em>BAP1</em> variants in the general population is not precisely known. According to the Genome Aggregation (gnomAD) database, the prevalence of germline loss-of-function variants in <em>BAP1</em> ranges between 0.007 to 0.613 percent, depending on the variant [<a href="#rid15">15</a>]. The most common variant is a p.Tyr401Ter variant (dbSNP [rs200156887]). An Australian population-based study detected <em>BAP1</em> germline variants in &lt;1 percent of patients with cutaneous melanoma from high-density melanoma families [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1540082060"><span class="h1">MOLECULAR PATHOGENESIS</span><span class="headingEndMark"> — </span>The <em>BAP1</em> tumor suppressor gene located on chromosome 3 (3p21.1) encodes the BRCA1-associated protein-1 (BAP1), a nuclear protein that functions as a deubiquitinating enzyme. It regulates the degradation of proteins and is involved in numerous cellular functions, including chromatin remodeling, transcriptional regulation, deoxyribonucleic acid (DNA) repair, and cell cycle regulation [<a href="#rid17">17</a>]. Germline <em>BAP1</em> variants are inherited in an autosomal dominant pattern with high penetrance.</p><p>In individuals with germline <em>BAP1</em> variants, most BIMs show biallelic loss of <em>BAP1</em>. One allele is inactivated through the germline mutation, and the other is somatically inactivated by several genetic alterations, such as chromosomal deletion involving the wild-type <em>BAP1</em> locus at 3p21, uniparental disomy of chromosome 3 with the mutated <em>BAP1</em>, or additional inactivating mutations. Biallelic loss of <em>BAP1</em> results in the loss of nuclear expression of BAP1 on immunohistochemistry in the large epithelioid melanocytes. (See <a class="local">'Immunohistochemistry'</a> below.)</p><p>Somatic inactivating mutations in <em>BAP1</em> were first identified in cases of sporadic metastasizing uveal melanoma [<a href="#rid6">6</a>] and, subsequently, in cutaneous tumors with features of atypical Spitz tumors in individuals from two unrelated families with autosomal dominantly inherited germline variants of <em>BAP1</em> [<a href="#rid12">12</a>]. Subsequently, inactivating <em>BAP1</em> somatic mutations were identified in morphologically similar tumors arising sporadically [<a href="#rid18">18</a>].</p><p>In addition to biallelic inactivation of BAP1, most BIMs also harbor driver mutations, most commonly <em>BRAF </em>V600E mutations or, less commonly, <em>NRAS</em> mutations, BRAF fusions, and RAF1 fusions [<a href="#rid19">19-21</a>]. In a series of 30 melanocytic lesions from three patients with <em>BAP1</em> germline variants and a family history of uveal melanoma, concurrent <em>BAP1</em> loss and <em>BRAF</em> V600E expression was seen in 67 percent of the tumors [<a href="#rid22">22</a>]. In a case report, a 35-year-old female patient with <em>BAP1</em> tumor predisposition syndrome presented with a melanocytic lesion harboring three histologically distinct melanocytic populations, indicating a progression from nevus to melanoma through a melanocytoma stage [<a href="#rid23">23</a>]. This progression was further supported by the finding of <em>BRAF</em> V600E, <em>BAP1</em>, and, interestingly, TERT-promoter (TERT-p) hotspot mutations.</p><p>Compared with conventional nevi, BIMs show loss of primary cilia and amplification of centrosomes. Primary cilium is an organelle involved in signal transduction and cell cycle progression. Studies have also shown a role for <em>BAP1</em> in centrosome and mitotic spindle formation [<a href="#rid24">24</a>]. Primary cilia have also been demonstrated to be absent in melanoma but retained in melanocytic nevi [<a href="#rid25">25</a>]. Therefore, centrosome and cilia formation are likely important in the pathogenesis of other BAP1-inactivated tumors.</p><p class="headingAnchor" id="H1853762075"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>BIMs present as 2 to 10 mm skin-colored to red-brown, dome-shaped or pedunculated papules, resembling intradermal nevi or cutaneous fibromas  (<a class="graphic graphic_picture graphicRef131177 graphicRef131185" href="/z/d/graphic/131177.html" rel="external">picture 1A-B</a>) [<a href="#rid11">11</a>]. Occasionally, they may present as brown, pigmented papules or tan macules [<a href="#rid26">26</a>].</p><p>Lesions are most frequently located on the head and neck, followed by trunk, upper limbs, and lower limbs [<a href="#rid26">26</a>]. BIMs can occur at any age but are predominantly seen in children and young adults [<a href="#rid21">21</a>].</p><p>Most BIMs are sporadic, occurring in individuals who do not carry germline variants in <em>BAP1</em>, and usually present as solitary lesions [<a href="#rid18">18</a>]. In contrast, in individuals carrying germline variants in <em>BAP1</em>, these tumors are generally multiple, first appear in the second or third decade of life, and increase in number with age [<a href="#rid1">1,9,27</a>]. The number of lesions typically ranges from 5 to 50 [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1980338319"><span class="h1">ASSOCIATION WITH BAP1 TUMOR PREDISPOSITION SYNDROME</span><span class="headingEndMark"> — </span>BAP1 tumor predisposition syndrome (MIM #614327), first described in 2011, is a rare autosomal dominant tumor predisposition syndrome caused by germline variants in the <em>BAP1</em> tumor suppressor gene [<a href="#rid2">2,8</a>]. Individuals with multiple BIMs have a high likelihood of carrying germline variants in <em>BAP1</em>, and approximately 70 percent of germline <em>BAP1</em> variant carriers have BIMs.</p><p>Individuals with germline <em>BAP1</em> variants have a high risk of developing malignancies at an early age, most frequently uveal melanoma, malignant mesothelioma, cutaneous melanoma, and renal cell carcinoma [<a href="#rid1">1,3-10</a>]. Other associated tumors include nonmelanoma skin cancer (predominantly basal cell carcinoma), meningioma, and cholangiocarcinoma [<a href="#rid28">28</a>].</p><p>In a worldwide study of 181 families with 804 individuals carrying <em>BAP1</em> variants, 88 percent of proband and 83 percent of nonproband variant carriers were found to have at least one tumor, suggesting that the risk of developing at least one tumor type may approach 100 percent over a lifetime [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H3486875407"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>BIM is often clinically misdiagnosed as an atypical Spitz tumor. The definitive diagnosis is based on histopathologic evaluation of the excised lesion and immunohistochemical demonstration of nuclear BAP1 loss. (See <a class="local">'Histopathology'</a> below.)</p><p>Genetic testing for germline <em>BAP1</em> variants should be performed in patients with multiple BIMs and/or a personal or family history of cancer to confirm or exclude BAP1 tumor predisposition syndrome. Individuals with a single isolated BIM in the absence of a significant family history for malignancies associated with the BAP1 tumor predisposition syndrome probably do not need to be routinely tested. (See <a class="local">'Association with BAP1 tumor predisposition syndrome'</a> above and <a class="local">'Genetic testing'</a> below.)</p><p class="headingAnchor" id="H3795855808"><span class="h2">Clinical findings and history</span><span class="headingEndMark"> — </span>The diagnosis of syndromic BIMs is suspected in a patient presenting with multiple skin-colored to red-brown, dome-shaped or pedunculated papules  (<a class="graphic graphic_picture graphicRef131177" href="/z/d/graphic/131177.html" rel="external">picture 1A</a>), predominantly located on the head and neck or trunk, and a personal or family history of cancer [<a href="#rid8">8,28</a>]. In these patients, it is reasonable to biopsy one or two lesions to confirm the diagnosis with histopathologic and immunohistochemical evaluation.</p><p>Sporadic, solitary lesions may be easily overlooked, as they resemble banal intradermal nevi or cutaneous fibromas in most cases. These lesions may come to attention if they have unusual features suspicious of skin cancer or because of the patient's concern.</p><p class="headingAnchor" id="H1620028543"><span class="h2">Dermoscopy</span><span class="headingEndMark"> — </span>Dermoscopy is of limited value in the clinical diagnosis of BIM. In a retrospective study of 48 histopathologically confirmed BIMs from 31 patients, the most prevalent dermoscopic pattern was a pink to tan, structureless area with irregular, eccentric dots and globules [<a href="#rid26">26</a>]. Other dermoscopic features include serpentine vessels, dotted vessels, and atypical network. Additionally, a structureless, pink background with central, bluish hue or light brown globules has been described [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2715525539"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Excisional biopsy for routine histopathologic evaluation and immunohistochemical demonstration of nuclear BAP1 loss is necessary for the diagnosis of BIM. Some experts suggest that in patients with multiple lesions demonstrating concerning clinical and/or dermoscopic findings, one or two lesions should be biopsied to confirm the diagnosis histopathologically and immunophenotypically.</p><p class="headingAnchor" id="H1147870055"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>A histopathologic spectrum of cytologic atypia exists for BIMs. The World Health Organization (WHO) classifies all lesions with both benign-appearing nevoid cells and minimal atypia and those with marked pleomorphism and large epithelioid cells as "BAP1 melanocytomas" [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1669440921"><span class="h3">Morphologic features</span><span class="headingEndMark"> — </span>Both sporadic and syndromic BIMs show similar clinical and histopathologic features in most cases. In one study, the presence of an extensive junctional component of epithelioid cells was the only morphologic feature showing a statistically significant association with germline <em>BAP1</em> mutations [<a href="#rid30">30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>At scanning magnification, BIMs appear as symmetric, dermal, melanocytic proliferations, with occasional involvement of the dermoepidermal junction [<a href="#rid18">18,26,31,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At higher magnification, lesions may show two different histologic patterns. One is characterized by uniformly large epithelioid cells with abundant eosinophilic cytoplasm, and the other is characterized by a biphasic proliferation of small nevoid cells and large epithelioid cells [<a href="#rid11">11,18,30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The epithelioid pattern displays uniformly large epithelioid "spitzoid" cells with well-defined cytoplasmic borders and sheet-like growth. This pattern was prominent in the cases initially described as atypical Spitz tumors or nevoid melanoma found to harbor an acquired <em>BAP1</em> mutation [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The biphasic pattern shows conventional, dermal-based clusters and nests of nevus cells, often located at the periphery of the tumor, and atypical epithelioid cells with abundant, eosinophilic, glassy cytoplasm, sometimes with a spitzoid appearance, often lacking melanin  (<a class="graphic graphic_picture graphicRef131178" href="/z/d/graphic/131178.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1">In both patterns, the epithelioid cells show variable cytologic atypia, with pleomorphic, hyperchromatic nuclei, and haphazard maturation. Mitotic activity is usually low. There is often an inflammatory infiltrate.</p><p></p><p>In a series of 102 BIMs (17 from eight patients with confirmed germline <em>BAP1</em> variants), the histopathologic features were broad and included [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Spitzoid cytomorphology (69 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Smaller epithelioid cells without spitzoid features (31 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Rhabdoid cytologic features (58 percent)</p><p></p><p>The spitzoid features noted in the majority of BIMs included [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large epithelioid cells with abundant, pale cytoplasms</p><p class="bulletIndent1"><span class="glyph">●</span>Marked variation in nuclear sizes</p><p class="bulletIndent1"><span class="glyph">●</span>Nuclear pleomorphism with dispersed chromatin patterns and prominent nucleoli</p><p></p><p>However, several histopathologic features typical of Spitz nevi were remarkably absent in BIMs [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Kamino bodies</p><p class="bulletIndent1"><span class="glyph">●</span>Spindled melanocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Epidermal hyperplasia and hypergranulosis</p><p class="bulletIndent1"><span class="glyph">●</span>Vertical ("raining down") orientation of junctional and dermal fascicles of melanocytes</p><p class="bulletIndent1"><span class="glyph">●</span>"V" or "wedge-shaped" dermal architectural configuration</p><p></p><p>Additional nuclear features that have been described include nuclear blebbing, nuclear budding, micronuclei, shadow nuclei, tetraploidy, peculiar cytoplasmic projections ("ant-bear cells") often containing micronuclei, and cell-in-cell structures (entosis) [<a href="#rid21">21</a>]. In addition, mixed nests of conventional nevus cells and BAP1-inactivated melanocytes with squeezed remnants of the original nevus have been observed [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3459507628"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>Immunohistochemical staining using an antibody specific to the C-terminal end of the BAP1 protein demonstrates the following [<a href="#rid30">30,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The large epithelioid cells of both sporadic and syndromic BIMs showed nuclear loss of BAP1 expression but retained cytoplasmic staining in a clumped perinuclear or fine granular pattern or combination of the two  (<a class="graphic graphic_picture graphicRef131178" href="/z/d/graphic/131178.html" rel="external">picture 2</a>). The nuclear loss of BAP1 staining is often coupled with diffuse, cytoplasmic staining for the BRAF V600E protein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, the background nevus cells show nuclear staining for BAP1 but are BRAF V600E negative.</p><p></p><p>Immunohistochemistry for BAP1 is sensitive and specific; however, false negatives occur [<a href="#rid34">34</a>]. Possible explanations include:</p><p class="bulletIndent1"><span class="glyph">●</span>BIM with inactivation of only one allele (eg, due to germline variant) may demonstrate retention of nuclear staining, as one wild-type copy of <em>BAP1</em> is functional.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Function-altering somatic or germline <em>BAP1</em> variants may affect either the nuclear localization sequence at the N-terminus, resulting in cytoplasmic retention, or the ubiquitin carboxy-terminal hydrolase catalytic domain at the C-terminus, altering the deubiquitinating activity [<a href="#rid9">9,27</a>]. However, milder mutations affecting the N-terminus may not compromise protein folding or stability and, thus, its transfer to the nucleus with an intact C-terminus, resulting in positive nuclear staining [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H3463135892"><span class="h2">What is the malignant potential of BAP1-inactivated melanocytomas?</span><span class="headingEndMark"> — </span>The vast majority of BIMs are indolent. However, those with an accumulation of atypical features, such as ulceration, large diameter (&gt;1 cm), nodule formation, high mitotic rate ≥6 mitoses per mm<sup>2</sup>, and high-grade atypia, should be considered tumors with uncertain malignant potential and suspicious for melanoma.</p><p>Immunohistochemical expression of the preferentially expressed antigen in melanoma (PRAME) has been demonstrated to assist in the diagnosis of primary cutaneous melanoma, which typically demonstrates diffuse and strong, positive nuclear staining [<a href="#rid36">36</a>]. In one study, five BIMs were analyzed with regard to PRAME, and none had an immunoreactivity score greater than +1 (1 to 25 percent of tumor cells positive) [<a href="#rid37">37</a>]. These results further support the notion that BIMs lack the typical immunophenotypic features of melanoma.</p><p>However, there are reports of progression of BIM into melanoma, likely as a result of additional genetic or epigenetic alterations [<a href="#rid12">12,23,38</a>].</p><p class="headingAnchor" id="H686023152"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of BIMs is broad and includes melanocytic and nonmelanocytic skin lesions that can mimic BIMs clinically. In many cases, histopathologic examination is necessary for the correct diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spitz nevus</strong> – Histologically, Spitz nevus  (<a class="graphic graphic_picture graphicRef85817 graphicRef131899" href="/z/d/graphic/85817.html" rel="external">picture 3A-B</a>) shows epidermal hyperplasia, Kamino bodies, vertical orientation of melanocytes, "V" or "wedge-shaped" configuration, large epithelioid cells with opaque cytoplasm, and large vesicular nuclei. Immunohistochemistry demonstrates nuclear BAP1 staining. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intradermal</strong> <strong>nevus</strong> – Intradermal nevus  (<a class="graphic graphic_picture graphicRef76961" href="/z/d/graphic/76961.html" rel="external">picture 4</a>) is a benign proliferation of nevus cells residing in the dermis that often lose their capacity to produce melanin. (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amelanotic/hypomelanotic melanoma</strong> – Amelanotic melanoma may exhibit a population of large epithelioid melanocytes with cytologic atypia devoid of melanin pigment or with minimal melanin pigment. (See  <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous neurofibroma</strong> – Neurofibromas  (<a class="graphic graphic_picture graphicRef82612" href="/z/d/graphic/82612.html" rel="external">picture 5</a>) consist of a bland spindle cell proliferation with coarse collagen. (See  <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Cutaneous neurofibroma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin tag (acrochordon)</strong> – Skin tags lack epithelioid melanocytes within the dermis. (See  <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Acrochordon (skin tag)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatofibroma</strong> – Dermatofibromas  (<a class="graphic graphic_picture graphicRef80587" href="/z/d/graphic/80587.html" rel="external">picture 6</a>) consist of spindled cells with collagen trapping and overlying epidermal induction that are negative for melanocytic markers. (See  <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Dermatofibroma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xanthogranuloma</strong> – Xanthogranuloma  (<a class="graphic graphic_picture graphicRef69122" href="/z/d/graphic/69122.html" rel="external">picture 7</a>) is a histiocytic tumor with Touton giant cells that are S100 negative. (See  <a class="medical medical_review" href="/z/d/html/13729.html" rel="external">"Juvenile xanthogranuloma (JXG)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular basal cell carcinoma</strong> – Basal cell carcinoma  (<a class="graphic graphic_picture graphicRef127426" href="/z/d/graphic/127426.html" rel="external">picture 8</a>) consists of nodules and/or strands of atypical basaloid cells that show nuclear palisading cellular apoptosis and scattered mitotic activity in the dermis. (See  <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2101760491"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H563604823"><span class="h2">Lesion management</span><span class="headingEndMark"> — </span>There are no specific evidence-based guidelines for the management of BIMs. Our approach is as follows [<a href="#rid14">14,39,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A lesion suspicious for BIM is initially excised with 2 mm margins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the lesion is low grade and the histologic margins are clear, no further treatment is required. If the lesion has positive margins, re-excision with 2 to 3 mm margins is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesions that are high grade with either negative or positive margins should be re-excised to achieve 5 to 10 mm margins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of lesions with undetermined malignant potential may be discussed in multidisciplinary consensus conferences.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with multiple BIMs, lesions that are not excised should be closely monitored clinically. Digital dermoscopic imaging may be considered to follow these patients [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H2390597106"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>DNA obtained from blood, saliva, or directly from tumors is subjected to Sanger sequencing or other sequencing for germline mutations in <em>BAP1</em>. Genetic testing for germline <em>BAP1</em> variants is indicated in the following circumstances [<a href="#rid34">34,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a confirmed diagnosis of BIM or melanocytic tumor of uncertain malignant potential and a personal or family history of at least one BAP1 tumor predisposition syndrome-related cancer (eg, mesothelioma, uveal melanoma, cutaneous melanoma, renal cell carcinoma) should be referred to a cancer genetic service for counseling and possible genetic testing [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young adults with multiple BIMs may benefit from genetic testing, even in the absence of a personal or family history of cancer, to exclude BAP1 tumor predisposition syndrome. Genetic counseling referral should be undertaken prior to decision making for genetic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is unclear whether there is a benefit for genetic testing in individuals with a solitary BIM and no personal/family history of cancer. These patients may undergo clinical surveillance for additional melanocytic tumors or cancer, including basal cell carcinoma [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H2803946571"><span class="h1">SURVEILLANCE FOR PATIENTS WITH <i>BAP1</i> GERMLINE VARIANTS</span><span class="headingEndMark"> — </span>There are no formal guidelines for cancer surveillance protocols for patients diagnosed with germline <em>BAP1</em> variants. A simulation model indicated that active surveillance for the main cancers associated with BAP1 tumor predisposition syndrome could reduce mortality, improve survival, and be cost effective for the health care system [<a href="#rid42">42</a>].</p><p>Proposed recommendations include [<a href="#rid1">1,2,17,27,41,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with germline <em>BAP1</em> mutations should receive routine skin and ophthalmologic examinations for cutaneous and uveal melanoma. (See  <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma", section on 'Surveillance and management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some experts recommend total skin examination every six months and annual ophthalmologic examinations starting at age 11 to 16 years [<a href="#rid1">1,8,41,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sun protection should be recommended. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of the increased risk of mesothelioma and kidney cancer, a multidisciplinary team is often necessary to screen for <em>BAP1</em>-related visceral malignancies, although there are no formal evidence-based guidelines on how that should be done.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For renal cell carcinoma, the surveillance recommendations are those for hereditary kidney cancer syndromes. (See  <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">"Hereditary leiomyomatosis and renal cell cancer (HLRCC)", section on 'Surveillance for renal cancer'</a> and  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Surveillance protocols'</a> and  <a class="medical medical_review" href="/z/d/html/100661.html" rel="external">"Birt-Hogg-Dubé syndrome", section on 'Surveillance'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mesothelioma, some experts suggest annual abdominal and respiratory clinical examination from the age of 30 years, with asymptomatic surveillance with ultrasound or magnetic resonance imaging (MRI) every two years [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H1998002714"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>BIMs are usually clinically stable and have an indolent course. Patients with BAP1 tumor predisposition syndrome have an increased cancer risk. Cutaneous melanoma has been reported in 18 to 23 percent of probands with germline <em>BAP1</em> variants, at a median age of approximately 45 years [<a href="#rid3">3,41,42</a>]. Risk may be higher for uveal melanoma (36 percent) and mesothelioma (25 percent) [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1356614322"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H4173424992"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and molecular pathogenesis</strong> – BAP1-inactivated melanocytomas (BIMs) are rare melanocytic tumors characterized by the loss of nuclear expression of the BRCA1-associated protein-1 (BAP1), a nuclear protein encoded by the <em>BAP1</em> tumor suppressor gene. Germline variants in <em>BAP1</em> cause BAP1 tumor predisposition syndrome, a rare autosomal dominant cancer predisposition syndrome. Carriers of <em>BAP1</em> variants often develop multiple BIMs and have an increased risk of developing uveal melanoma, malignant mesotheliomas, cutaneous melanoma, renal cell carcinoma, and other internal cancers. (See <a class="local">'Introduction'</a> above and <a class="local">'Molecular pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – BIMs present as skin-colored to red-brown, dome-shaped or pedunculated papules, ranging in diameter from 2 to 10 mm  (<a class="graphic graphic_picture graphicRef131177 graphicRef131185" href="/z/d/graphic/131177.html" rel="external">picture 1A-B</a>). In individuals carrying germline variants in <em>BAP1</em>, these tumors are generally multiple, appear in the second or third decade of life, and increase in number with age. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The definitive diagnosis of BIM is based on histopathologic evaluation of the excised lesion and immunohistochemical demonstration of nuclear BAP1 loss. Genetic testing for germline <em>BAP1</em> variants should be performed in patients with BIMs and a personal or family history of at least one BAP1 tumor predisposition syndrome-related cancer (ie, mesothelioma, uveal melanoma, cutaneous melanoma, renal cell carcinoma) and for young adults with multiple BIMs in the absence of a family or personal history of cancer to confirm or exclude BAP1 tumor predisposition syndrome. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Histopathology'</a> above and <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential is broad and includes melanocytic and nonmelanocytic skin lesions (Spitz nevus, amelanotic/hypomelanotic melanoma, neurofibroma, dermatofibroma, xanthogranuloma, nodular basal cell carcinoma). (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There are no specific evidence-based guidelines for the management of BIMs. Lesions are typically diagnosed as BIMs via excision, as discussed above (see <a class="local">'Diagnosis'</a> above). Our approach to lesion management is as follows (see <a class="local">'Lesion management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For lesions with low-grade histologic atypia excised with clear margins, no further intervention is needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For lesions with low-grade histologic atypia and positive margins, we suggest re-excision with 2 to 3 mm margins (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For lesions showing high-grade histologic atypia with or without positive margins, we suggest re-excision to achieve 5 to 10 mm margins (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a prior diagnosis of BIM who present with <strong>multiple</strong> lesions suspicious for BIM, we advise genetic testing for germline variants in <em>BAP1</em> to exclude BAP1 tumor predisposition syndrome (see <a class="local">'Genetic testing'</a> above). Irrespective of the results of genetic testing:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For lesions that exhibit clinical changes, we suggest excision rather than observation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lesions without clinical changes can be monitored clinically and dermoscopically.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – BIMs are usually clinically stable and have an indolent course. Patients with BAP1 tumor predisposition syndrome have an increased risk of uveal melanoma, mesothelioma, renal cell carcinoma, and cutaneous melanoma. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Star P, Goodwin A, Kapoor R, et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer 2018; 92:48.</a></li><li><a class="nounderline abstract_t">Battaglia A. The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment. Clin Med Insights Oncol 2014; 8:37.</a></li><li><a class="nounderline abstract_t">Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012; 10:179.</a></li><li><a class="nounderline abstract_t">Cheung M, Talarchek J, Schindeler K, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013; 206:206.</a></li><li><a class="nounderline abstract_t">de la Fouchardière A, Cabaret O, Savin L, et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 2015; 88:273.</a></li><li><a class="nounderline abstract_t">Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410.</a></li><li><a class="nounderline abstract_t">Höiom V, Edsgärd D, Helgadottir H, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer 2013; 52:378.</a></li><li class="breakAll">Pilarski R, Carlo M, Cebulla C, Abdel-Rahman M. BAP1 tumor predisposition syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 2016.</li><li><a class="nounderline abstract_t">Haugh AM, Njauw CN, Bubley JA, et al. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol 2017; 153:999.</a></li><li><a class="nounderline abstract_t">Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol 2018; 30:102.</a></li><li><a class="nounderline abstract_t">Zhang AJ, Rush PS, Tsao H, Duncan LM. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol 2019; 46:965.</a></li><li><a class="nounderline abstract_t">Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43:1018.</a></li><li class="breakAll">World Health Organization Classification of Skin Tumors, 5th edition online. Editorial Board, International Agency for Research on Cancer, 2023. https://tumourclassification.iarc.who.int/welcome/ (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. JAMA Netw Open 2023; 6:e2250613.</a></li><li class="breakAll">Genome Aggregation Database. https://gnomad.broadinstitute.org/ (Accessed on December 18, 2023).</li><li><a class="nounderline abstract_t">Aoude LG, Gartside M, Johansson P, et al. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases. Twin Res Hum Genet 2015; 18:126.</a></li><li><a class="nounderline abstract_t">Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol 2016; 74:411.</a></li><li><a class="nounderline abstract_t">Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012; 36:818.</a></li><li><a class="nounderline abstract_t">Blokx WA, Rabold K, Bovenschen HJ, et al. NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report. Virchows Arch 2015; 466:117.</a></li><li><a class="nounderline abstract_t">Roy SF, Milante R, Pissaloux D, et al. Spectrum of Melanocytic Tumors Harboring BRAF Gene Fusions: 58 Cases With Histomorphologic and Genetic Correlations. Mod Pathol 2023; 36:100149.</a></li><li><a class="nounderline abstract_t">Donati M, Martinek P, Steiner P, et al. Novel insights into the BAP1-inactivated melanocytic tumor. Mod Pathol 2022; 35:664.</a></li><li><a class="nounderline abstract_t">Piris A, Mihm MC Jr, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol 2015; 46:239.</a></li><li><a class="nounderline abstract_t">Donati M, Šteiner P, Kazakov DV. BAP1-Inactivated Melanoma Arising From BAP1-Inactivated Melanocytic Tumor in a Patient With BAP1 Germline Mutation: A Case Report and Review of the Literature. Am J Dermatopathol 2023; 45:117.</a></li><li><a class="nounderline abstract_t">Singh A, Busacca S, Gaba A, et al. BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene 2023; 42:572.</a></li><li><a class="nounderline abstract_t">Kim J, Dabiri S, Seeley ES. Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma. PLoS One 2011; 6:e27410.</a></li><li><a class="nounderline abstract_t">Yélamos O, Navarrete-Dechent C, Marchetti MA, et al. Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society. J Am Acad Dermatol 2019; 80:1585.</a></li><li><a class="nounderline abstract_t">Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013; 13:153.</a></li><li><a class="nounderline abstract_t">Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst 2018; 110:1328.</a></li><li><a class="nounderline abstract_t">Buljan M, Marušić Z, Franceschi N. Dermoscopy of BAP1-inactivated melanocytic tumours. Australas J Dermatol 2022; 63:86.</a></li><li><a class="nounderline abstract_t">Garfield EM, Walton KE, Quan VL, et al. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors. J Am Acad Dermatol 2018; 79:525.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Pérez-Gónzalez YC, Requena L, Kutzner H. Histopathologic clues for the diagnosis of Wiesner nevus. J Am Acad Dermatol 2014; 70:549.</a></li><li><a class="nounderline abstract_t">Wiesner T, Kutzner H, Cerroni L, et al. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology 2016; 48:113.</a></li><li><a class="nounderline abstract_t">Gammon B, Traczyk TN, Gerami P. Clumped perinuclear BAP1 expression is a frequent finding in sporadic epithelioid Spitz tumors. J Cutan Pathol 2013; 40:538.</a></li><li><a class="nounderline abstract_t">Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 2013; 45:116.</a></li><li><a class="nounderline abstract_t">Duncan LM, Tetzlaff MT. BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue! J Cutan Pathol 2020; 47:459.</a></li><li><a class="nounderline abstract_t">Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol 2018; 42:1456.</a></li><li><a class="nounderline abstract_t">Lopez DR, Forcucci JA, O'Connor H, Maize JC. PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study. J Cutan Pathol 2021; 48:597.</a></li><li><a class="nounderline abstract_t">Wiesner T, Fried I, Ulz P, et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol 2012; 30:e337.</a></li><li><a class="nounderline abstract_t">de la Fouchardiere A, Blokx W, van Kempen LC, et al. ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch 2021; 479:3.</a></li><li class="breakAll">National Cancer Institute at the National Institutes of Health. Childhood Melanoma Treatment (PDQ) – Health Professional Version. https://www.cancer.gov/types/skin/hp/child-melanoma-treatment-pdq (Accessed on December 20, 2023).</li><li><a class="nounderline abstract_t">Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 2016; 89:285.</a></li><li><a class="nounderline abstract_t">Walpole S, Hayward NK, Pritchard AL, Johansson PA. Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers. JCO Clin Cancer Inform 2021; 5:143.</a></li><li><a class="nounderline abstract_t">Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 2014; 53:177.</a></li></ol></div><div id="topicVersionRevision">Topic 129132 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413689" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855403" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935333" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849051" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25080371" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Germline BAP1 mutations predispose also to multiple basal cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051595" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frequent mutation of BAP1 in metastasizing uveal melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341325" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hereditary uveal melanoma: a report of a germline mutation in BAP1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341325" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hereditary uveal melanoma: a report of a germline mutation in BAP1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28793149" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29988936" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31233225" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : BRCA1-associated protein (BAP1)-inactivated melanocytic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874003" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Germline mutations in BAP1 predispose to melanocytic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874003" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Germline mutations in BAP1 predispose to melanocytic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36630138" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36630138" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25787093" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892651" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22367297" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342144" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36841436" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spectrum of Melanocytic Tumors Harboring BRAF Gene Fusions: 58 Cases With Histomorphologic and Genetic Correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34857909" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Novel insights into the BAP1-inactivated melanocytic tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25479927" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36669076" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : BAP1-Inactivated Melanoma Arising From BAP1-Inactivated Melanocytic Tumor in a Patient With BAP1 Germline Mutation: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36550359" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096570" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30244062" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23550303" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : BAP1 and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517737" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398452" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dermoscopy of BAP1-inactivated melanocytic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753057" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373783" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Histopathologic clues for the diagnosis of Wiesner nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27020384" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23495950" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clumped perinuclear BAP1 expression is a frequent finding in sporadic epithelioid Spitz tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23277170" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tumours associated with BAP1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32096236" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30045064" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : PRAME Expression in Melanocytic Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33094849" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032617" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33432480" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33432480" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096145" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33513031" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24243779" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
